HIV / AIDS

A new commentary argues that given the strong safety and efficacy profile of TDF/FTC, there is not sufficient benefit to warrant changing clinician emphasis to TAF/FTC.

The prevalence of NTDs in pregnancies among women with diagnosed HIV infection was 7.0 per 10,000 live births, which was similar to that among the general population.

Pamela Gorman, RN, ACRN, describes the benefits of connecting care to incarcerated people with HIV.

New legislation, cost assistance program will likely reduce transmission.

Pamela Gorman, RN, ACRN, describes a transitional care coordination program for incarcerated individuals with HIV returning to the community primary care setting.

Roughly half of all American expectant mothers living with HIV are receiving treatments that don’t meet federal guidelines. A new study examines prescribing choices for this population.

A new study found that the estimated time from HIV seroconversion to initiation of ART was reduced by 42% between 2006 and 2015 in New York City.

Rasheeta Chandler, PhD, RN, APRN-BC, FNP-BC, FAANP, FAAN, explains the need to incorporate women at-risk for or living with HIV into the decision-making process if we are to end the epidemic.

Max Brito, MD, MPH, remarks on the underrepresentation of transgender women in HIV and other sexual health research.

Viral suppression at 2 years nearly doubled for people with HIV in a medical care coordination program implemented by the Los Angeles County Division of HIV and STD Programs, a new study found.

Investigators of a new, multisite study evaluating neuropsychological development in African school-age kids found that children with perinatally-acquired HIV had poorer results on neuropsychological tests despite early ART initiation and viral suppression.

A recent study published in Transgender Health analyzed transgender and gender-nonconforming ART adherence based on the US Trans Survey, the largest survey of TGNC people in the United States.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses noteworthy infectious disease papers published in 2019.

A recent commentary discusses the need to uncover diagnostic and prognostic biomarkers for HIV-associated neurocognitive disorder (HAND).

Daniel B. Chastain, PharmD, BCIDP, AAHIVP, discusses a retrospective study of errors occurring in the treatment of patients with HIV.

Contagion® counts down the top HIV news stories of 2019, including FDA approvals, breakthrough discoveries, recommendations from the frontlines, and a big-picture look at just how close we are to ending the epidemic.

A new study out of Africa demonstrates that maternal-child clinics may act as a one-stop shop for both pregnancy and postpartum concerns and HIV protection.

Jason Tokumoto, MD, discusses how occupying the role of both patient and physician can provide a human perspective on HIV care.

Efforts to screen for TB in people newly diagnosed with HIV hopefully will lower death rates.

An analysis shows that during 2016-17, 14% of people living with HIV have used a drug-cost saving strategy and 7% have had cost saving-related nonadherence.

Results suggest that PrEP provision is concentrated among those at high risk for HIV and STIs, but that more must be done to prevent STIs among those who persistently use PrEP.

Recommendations to offer antiretroviral therapy on the same day as home-based HIV testing were reinforced by a 2-year follow-up study that examined involvement in care and viral suppression.

Jason Tokumoto, MD, discusses recent developments in HIV treatment and prevention, focusing on the impact of “U=U.”

Jason Schafer, PharmD, MPH, BCPS AQ-ID, discusses upcoming long-acting therapies for HIV.

Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.

An analysis of participants in a trial measuring the efficacy of PrEP found that sex-driven dose timing—as opposed to daily dosing—was effective in preventing HIV, even in men who had sex less often.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the December issue.

In April, the US Food and Drug Administration (FDA) approved dolutegravir plus lamivudine as a complete 2-drug regimen for treatment naïve adults with HIV-1.

Observations about the body’s response to malaria infection can lead to new treatments for HIV and lupus, investigators believe.

Gregory Felzien, MD, AAHIVS, highlights “clinic champions” who help move patient care forward while facing external constraints.